Bayer : Poor glyphosate business triggers FY 2023 profit warning
>EBITDA guidance down by 9% - preliminary Q2 figures below consensus - Yesterday (24. July) evening, Bayer published a profit warning for FY 2023. The expected top line is now € 48.5 - 49.5bn (previously: € 51 - 52bn; ODDO BHF estimates were at: € 51bn), the new guidance for the adj. EBITDA is € 11.3 - 11.8bn (€ 12.5 - 13bn; € 12.5bn), expected core EPS is € 6.20 - 6.40 (€ 7.20 - € 7.40; € 7.16) and FCF should be at breakeven level after previously expecting € 3bn. Fu...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.